FibroScan‑Based Assessment and Management in Fatty Liver Disease

1. Interpretation Thresholds for Liver Stiffness Measurement (LSM)

LSM < 8 kPa rules out advanced fibrosis (F3‑F4) with 93 % sensitivity and allows management in primary‑care or endocrinology settings – American College of Endocrinology and American Association of Clinical Endocrinologists 1.
LSM > 12 kPa strongly suggests advanced fibrosis (positive predictive value ≈ 76 % in diabetes clinics and ≈ 88 % in hepatology clinics) and mandates immediate referral to hepatology – American College of Endocrinology and American Association of Clinical Endocrinologists 1.
When LSM > 12 kPa and FIB‑4 > 2.67, liver biopsy should be considered – American College of Endocrinology and American Association of Clinical Endocrinologists 7.
Patients with LSM > 12 kPa and confirmed cirrhosis should start hepatocellular carcinoma surveillance – American College of Endocrinology and American Association of Clinical Endocrinologists 7.

CAP quantifies hepatic steatosis and is obtained simultaneously with LSM – Journal of Hepatology 3.
CAP ≥ 280 dB/m indicates hepatic steatosis; when combined with elevated AST (>17 IU/L women, >20 IU/L men) it helps identify presumed metabolic‑associated steatotic hepatitis (MASH) – Clinical Gastroenterology and Hepatology 4.
CAP > 275 dB/m provides >90 % sensitivity for detecting steatosis, but ultrasound remains the preferred first‑line imaging – Journal of Hepatology 3.
CAP does not predict liver‑related outcomes or mortality; it solely reflects fat content – Diabetologia 6.

Use the XL probe for patients with BMI ≥ 30 kg/m² or skin‑to‑liver capsule distance ≥ 2.5 cm; this reduces scan failure from 5‑20 % to <5 % – Clinical and Molecular Hepatology 8.
M and XL probes have comparable diagnostic performance when appropriately selected – Clinical and Molecular Hepatology 8.
Perform FibroScan after at least 3 hours of fasting – Clinical Gastroenterology and Hepatology 4.
Elevated ALT ≥ 100 IU/L impairs LSM accuracy – Clinical and Molecular Hepatology 8.
Acceptable study quality requires ≥10 valid measurements, an interquartile range < 30 % of the median LSM, and verification that rib echo is absent – Clinical Gastroenterology and Hepatology 4.

Calculate FIB‑4 before ordering FibroScan – American College of Endocrinology and American Association of Clinical Endocrinologists 1.
FIB‑4 < 1.3 (or < 2.0 in patients ≥ 65 y) denotes low fibrosis risk; FibroScan is optional – American College of Endocrinology and American Association of Clinical Endocrinologists 1.
FIB‑4 1.3–2.67 is indeterminate; proceed to FibroScan – American College of Endocrinology and American Association of Clinical Endocrinologists 1.
FIB‑4 > 2.67 indicates high risk; FibroScan is recommended and, if LSM > 12 kPa, biopsy should be strongly considered – American College of Endocrinology and American Association of Clinical Endocrinologists 1.

Continue obesity and cardiovascular risk management; aim for 7–10 % body‑weight loss – American College of Endocrinology and American Association of Clinical Endocrinologists 7.
Repeat FibroScan every 2–3 years – American College of Endocrinology and American Association of Clinical Endocrinologists 1.

Refer to hepatology for further evaluation, including proprietary fibrosis biomarkers (e.g., Enhanced Liver Fibrosis test) or MR elastography – American College of Endocrinology and American Association of Clinical Endocrinologists 1.

Immediate hepatology referral for comprehensive assessment – American College of Endocrinology and American Association of Clinical Endocrinologists 1.

If CAP > 300 dB/m and LSM 10–12 kPa, supplement assessment with the NAFLD Fibrosis Score or Enhanced Liver Fibrosis test – Clinical and Molecular Hepatology 8.
In patients with BMI > 35 kg/m² despite using an XL probe, consider MR elastography (AUROC 0.84–0.93) for higher accuracy – American College of Endocrinology and American Association of Clinical Endocrinologists; Endocrine practice [2][11].
When FIB‑4 and LSM results conflict, refer to hepatology for additional testing – American College of Endocrinology and American Association of Clinical Endocrinologists 1.
If clinical suspicion of cirrhosis exists despite LSM < 12 kPa, proceed to liver biopsy or MR elastography – American College of Endocrinology and American Association of Clinical Endocrinologists 7.